Angel Biotechnology Holdings (LSE:ABH) EBITDA Margin %: -261.68% (As of Sep. 2012)


What is Angel Biotechnology Holdings EBITDA Margin %?

Angel Biotechnology Holdings LSE:ABH EBITDA Margin % is -261.68% as of Sep. 2012. The stock has 2 warning signs investors should review.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Angel Biotechnology Holdings's EBITDA for the six months ended in Sep. 2012 was £-2.80 Mil. Angel Biotechnology Holdings's Revenue for the six months ended in Sep. 2012 was £1.07 Mil. Therefore, Angel Biotechnology Holdings's EBITDA margin for the quarter that ended in Sep. 2012 was -261.68%.

Angel Biotechnology Holdings  (LSE:ABH) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Angel Biotechnology Holdings EBITDA Margin % Related Terms

Angel Biotechnology Holdings EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Angel Biotechnology Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Angel Biotechnology Holdings EBITDA Margin % Chart

Angel Biotechnology Holdings Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec07 Dec08 Dec09 Dec10 Mar12
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only -268.85 -106.72 -44.85 10.76 -33.54

Angel Biotechnology Holdings Semi-Annual Data
Jun05 Dec05 Jun06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Mar12 Sep12
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.51 9.97 -12.62 0.00 -261.68

Angel Biotechnology Holdings EBITDA Margin % Competitor Comparison

For the Biotechnology subindustry, Angel Biotechnology Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Angel Biotechnology Holdings EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Angel Biotechnology Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Angel Biotechnology Holdings's EBITDA Margin % falls into.


Angel Biotechnology Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Angel Biotechnology Holdings's EBITDA Margin % for the fiscal year that ended in Mar. 2012 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2012 )/Revenue (A: Mar. 2012 )
=-1.159/3.456
=-33.54 %

Angel Biotechnology Holdings's EBITDA Margin % for the quarter that ended in Sep. 2012 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2012 )/Revenue (Q: Sep. 2012 )
=-2.8/1.07
=-261.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -261.68% mean?
Angel Biotechnology Holdings (LSE:ABH) has a EBITDA Margin % of -261.68% as of Sep. 2012. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Angel Biotechnology Holdings and its competitors.
Is Angel Biotechnology Holdings' EBITDA Margin % too high?
Angel Biotechnology Holdings' current EBITDA Margin % is -261.68%.
How does Angel Biotechnology Holdings' EBITDA Margin % compare to competitors?
Angel Biotechnology Holdings' EBITDA Margin % of -261.68% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Angel Biotechnology Holdings and its competitors. Angel Biotechnology Holdings's current EBITDA Margin % is -261.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angel Biotechnology Holdings stock overvalued right now?
Angel Biotechnology Holdings (LSE:ABH) has a current EBITDA Margin % of -261.68%. The current EBITDA Margin % is -261.68%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Angel Biotechnology Holdings (LSE:ABH), the current EBITDA Margin % is -261.68% as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.